| Not Yet Recruiting | Calcium Channel Blocker in Myotonic Dystrophy Type 1 NCT07075965 | University of Rochester | Phase 1 |
| Recruiting | An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE) NCT07220603 | PepGen Inc | Phase 2 |
| Enrolling By Invitation | The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Followi NCT07072676 | LMU Klinikum | N/A |
| Enrolling By Invitation | Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 NCT07008469 | Avidity Biosciences, Inc. | Phase 3 |
| Recruiting | The Spanish National Registry for Myotonic Dystrophy Type 1 NCT07385443 | Fundació Institut Germans Trias i Pujol | — |
| Recruiting | A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 NCT06667453 | PepGen Inc | Phase 2 |
| Recruiting | Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease) NCT05532813 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Recruiting | Study of ATX-01 in Participants With DM1 NCT06300307 | ARTHEx Biotech S.L. | Phase 1 / Phase 2 |
| Active Not Recruiting | Global Study of Del-desiran for the Treatment of DM1 NCT06411288 | Avidity Biosciences, Inc. | Phase 3 |
| Recruiting | Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology NCT07136844 | Centre Hospitalier Universitaire de Liege | N/A |
| Recruiting | Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy NCT06138743 | Arrowhead Pharmaceuticals | Phase 1 / Phase 2 |
| Unknown | Home-based Training and Supplementation in DM1 Patients NCT05848830 | McMaster University | Phase 3 |
| Completed | Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1 NCT06204809 | PepGen Inc | Phase 1 |
| Withdrawn | Evaluation of Cognitive Functions in 20 Patients With Type 1 Myotonic Dystrophy With Virtual Reality Approach NCT06270186 | Centre Hospitalier Universitaire de Nice | N/A |
| Completed | Profile of Dysphagia in Myotonic Dystrophy Type 1 (DM1) NCT05865483 | University College, London | — |
| Recruiting | Myotonic Dystrophy Type 1 Congenital and Juvenile Form: From Diagnosis to Rehabilitation [MDCJ-NeuBeRe] NCT06378216 | IRCCS Eugenio Medea | — |
| Unknown | Observational Study of Digital Biomarkers of Myotonia and Gait in Adults and Children With Myotonic Dystrophy NCT06089018 | Stanford University | — |
| Completed | Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients NCT05479981 | Avidity Biosciences, Inc. | Phase 2 |
| Completed | Effects of a 12-week Strength Training Program in Women With Myotonic Dystrophy Type 1 NCT05400629 | Université de Sherbrooke | N/A |
| Completed | Symptoms and Outcome Measures for Upper- Limb Function in Myotonic Dystrophy Type 1 NCT05006924 | Oslo University Hospital | — |
| Completed | Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients NCT05027269 | Avidity Biosciences, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Myotonic Dystrophy - Vascular and Cognition NCT04656210 | University Hospital, Lille | — |
| Completed | Low-frequency Repetitive Nerve Stimulation in Myotonic Dystrophy Type 1 NCT05662150 | Vrije Universiteit Brussel | N/A |
| Enrolling By Invitation | A Multicenter Phenotype-Genotype Analysis of DM1 Patients in China NCT06101940 | Huashan Hospital | — |
| Completed | Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients NCT04886518 | Harmony Biosciences Management, Inc. | Phase 2 |
| Completed | Myotonic Dystrophy Type 1 and Resistance Exercise NCT05036447 | Norwegian School of Sport Sciences | N/A |
| Completed | Effect of MYODM on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1 NCT04634682 | Myogem Health Company, S.L. | N/A |
| Completed | Poor Neck Proprioception May Cause Balance Deficits in Myotonic Dystrophy 1 NCT04712422 | Istituto Auxologico Italiano | — |
| Unknown | NIPD on cffDNA for Triplet Repeat Diseases NCT04698551 | University Hospital, Montpellier | — |
| Recruiting | Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study NCT05982119 | Centre Hospitalier Universitaire de Liege | N/A |
| Completed | Myotonic Dystrophy Type 1 Aerobic Exercise Study NCT04187482 | McMaster University | N/A |
| Completed | DM-IMT - Controlled, Randomized, Three-arm Intervention Study on the Safety and Efficacy of Regular Respirator NCT04052958 | LMU Klinikum | N/A |
| Recruiting | Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) NCT03981575 | Virginia Commonwealth University | — |
| Completed | Venous Thromboembolism in Myotonic Dystrophy Type 1 NCT03424460 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Effects of a 12-week Strength Training Program in Men With Myotonic Dystrophy Type 1 NCT04018820 | Élise Duchesne | N/A |
| Unknown | Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy NCT02880735 | National Institute of Respiratory Diseases, Mexico | N/A |
| Completed | Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy NCT02858908 | AMO Pharma Limited | Phase 2 |
| Completed | Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1 NCT02251457 | Ohio State University | Phase 1 |
| Completed | Effects of a Multiple Component Training Program on Muscles in Adults With Myotonic Dystrophy Type 1 NCT04001920 | Cynthia Gagnon | N/A |
| Recruiting | Myotonic Dystrophy Family Registry NCT02398786 | Myotonic Dystrophy Foundation | — |
| Unknown | Sudden Cardiac Death Stratification in Myotonic Dystrophy Type 1 Patients NCT03784586 | University of Campania Luigi Vanvitelli | — |
| Completed | Tracking the Brain in Myotonic Dystrophies: a 5-year Longitudinal Follow-up Study NCT02729597 | University Hospital, Bonn | — |
| Completed | Venous Thromboembolism in DM1 NCT03141749 | Institut de Myologie, France | — |